Stereotactic Body Radiotherapy as Treatment for Organ Confined Low and Intermediate Risk Prostate Carcinoma, a Seven Year Study

Abstract

Read online

Objectives: Stereotactic body radiation therapy (SBRT) takes advantage of the prostate’s low α/β ratio to deliver a large radiation dose in few fractions. Initial studies on small groups of low-risk patients support SBRT’s potential for clinical efficacy while limiting treatment-related morbidity and maintained quality of life (QOL). This prospective study expands upon prior studies to further evaluate SBRT efficacy for a large patient population with organ confined, low- and intermediate-risk prostate cancer patients. Methods: 477 patients with prostate cancer received CyberKnife SBRT. The median age was 68.6 years and the median PSA was 5.3 ng/ml. 324 patients were low-risk (PSA 10, or Gleason 3+4 with PSA <10; n=106) had a significantly higher bDFS than patients with high intermediate-risk (Gleason 3+4 with PSA 10-20 or Gleason 4+3; n=47), with bDFS of 93.5% versus 79.3%, respectively. For the low and low intermediate-risk groups, there was no difference in median PSA nadir or biochemical disease control between doses of 35 and 36.25 Gy. Conclusions: CyberKnife SBRT produces excellent biochemical control rates. Median PSA levels compare f

Keywords

• Prostate
• Radiotherapy
• Cancer
• stereotactic
• Confined Spaces